Greenwich LifeSciences Inc (GLSI) - Debt to Equity

Greenwich LifeSciences (GLSI) conducts its development within a stable US jurisdiction, eliminating external trade risks. The company is creating peptide vaccines to destroy residual tumors, demonstrating an absence of recurrence in GP2 tests. The drug design process relies on AI and automation, although final research remains the responsibility of physicians. This price chart for shares on GURU.Markets shows that the total debt-to-equity ratio is 0.00.

Sustainable funding for long-term development is critical for the biotechnology sector. This metric measures the proportion of borrowed funds within the asset structure relative to equity. By analyzing the debt-to-equity ratio of Greenwich LifeSciences (GLSI), an investor assesses the risk of bankruptcy in the absence of revenue. This is particularly relevant for Greenwich LifeSciences (GLSI), as vaccine trial costs are depleting liquidity. An increase in this indicator signals a critical dependence on creditors.